FOR IMMEDIATE RELEASE
New Clinical Study Shows Biophoton Technologies Aid in Cognitive Recovery for Alzheimer's Patients
Study Results Shared Today at Alzheimer’s Association International Conference (AAIC) in Philadelphia
Philadelphia, PA, July 27, 2024 — Recent findings from a new clinical study suggest that biophoton technologies improve cognitive functions and quality of life in individuals with moderate or severe Alzheimer's disease. These findings were presented today, July 27, 2024, during the Tech and Dementia Conference, a pre-conference event of the Alzheimer’s Association International Conference (AAIC), and will also be highlighted during the AAIC conference held from July 28 to August 1 in Philadelphia, PA, USA.
Led by Principal Investigator Dr. Mariola Smotrys at the First Institute of All Medicines (FIAM), the study examined the effects of Ultra-High Biophoton Technologies on patients with moderate to severe Alzheimer's disease. Results indicated potential improvements in cognitive functions, as reflected by reductions in at least five Alzheimer’s questionnaire scores, including memory, orientation, functional ability, visuospatial skills, language, and communication. Additionally, the study reported improved quality of life for Alzheimer’s patients.
Dr. Lawrence Alpert, the study physician, shared his positive outlook on these findings. "Our previous studies and this one suggest that biophoton technologies, currently marketed as a wellness product, have the potential to address cognitive decline associated with Alzheimer's disease. Based on my weekly examination, I see this method could quickly enhance the quality of life for many Alzheimer’s patients in days or weeks, not months."
The Alzheimer’s Association International Conference is the most significant international meeting focused on advancing Alzheimer's and dementia research. This year’s conference gathered thousands of researchers, clinicians, and care professionals from around the world to discuss the latest studies, theories, and discoveries. The results of this study provided an opportunity for medical scientists and neurologists to discuss how to advance research for Alzheimer’s.
Scientists observed that biophoton technologies utilize advanced technology to emit light particles (biophotons) that interact with the body’s cells, potentially promoting healing and regeneration. The success of this study represents a significant step in biophoton research and its possible implications for treating neurodegenerative diseases.
Forward-Looking Statements
This press release contains forward-looking statements that involve risks and uncertainties. These statements include, but are not limited to, the potential benefits of the Biophoton technologies. Factors that could cause actual results to differ materially include risks that clinical development activities may be delayed or unsuccessful, that products may not be approved or commercially viable, and that regulatory decisions may be unfavorable. First Institute of All Medicines (FIAM) disclaim any obligation to update these statements after the date hereof, except as required by law.
About the First Institute of All Medicines (FIAM)
The First Institute of All Medicines (FIAM) is a nonprofit organization focused on researching and promoting treatments for chronic diseases. FIAM is dedicated to conducting clinical studies and offering support, education, and advocacy for patients with brain injuries and their families and caregivers.
Contact:
For more information about the Biophoton Technology and the clinical studies, please visit www.firstallmed.org
